Skip to content

Last week in biopharma partnering: June 5 – June 25, 2022

By pharma3dadmin June 27, 2022

Each week (well almost, some weeks are quite uneventful), we compile and curate hot-off-the-press news and updates on the happenings in the world of pharma and life sciences partnering.

Be sure to follow us and keep up-to-date on all things partnering to inform your decisions and strategies.

Medison Pharma Ltd. announced today an exclusive multi-regional agreement with Argenx to commercialize efgartigimod in 14 countries, across Europe and Israel, for the treatment of adult patients with generalized myasthenia gravissee full article.

Soleo Health, provider of specialty pharmacy services, announced it was named one of only four limited distribution drug (LDD) specialty pharmacy partners to dispense nationwide RADICAVA ORS® (edaravone) oral suspension, commercialized by Mitsubishi Tanabe Pharma America, Inc. (MTPA) – see full article.

After layoffs and reshuffling of its R&D leadership, Agios is preparing for a new approach to innovation via business development and partnerships to advance its programs – see full article.

Owkin, with its artificial intelligence-powered clinical development platform, signs another pharma partner – Bristol-Myers Squibb; the deal is split between a Series B financing led by BMS and upfront fees of $80 million – see full article.

Dren Bio announces $65 Million Series B financing – with Pfizer as one of its marquee investors – to take its lead asset into the clinic and accelerate development of new product candidates from its targeted Myeloid Engager and Phagocytosis Platformsee press release.

Vipergen, provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced multi-target drug discovery partnership with LEO Pharma focused on novel treatments for dermatology indications – see full article.

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. , a San Diego-based pre-clinical stage biotech company dedicated to the discovery and development of next-generation cytokine therapies to treat immuno-oncology and autoimmune diseases – see press release.

Humanigen, a late-stage clinical biopharmaceutical company, and PCI Pharma Services, a global contract development and manufacturing organization (CDMO) , announced an agreement for commercialization of lenzilumab, a first-in-class monoclonal antibody that has been shown to neutralize granulocyte-macrophage colony-stimulating factor (GM-CSF) associated with COVID-19 and other indications – see full article.

The University of Texas MD Anderson Cancer Center, Invectys and the Cell Therapy Manufacturing Center (CTMC) have entered a strategic partnership to co-develop a compliant and mountable process for human leukocyte antigen (HLA)-G targeted chimeric antigen receptor (CAR) T cell therapy to treat solid tumours – see full article.

Valneva SE, a specialty vaccine company, and Pfizer Inc. announced the closing of the equity investment where Pfizer has invested €90.5 ($95) million in Valneva, representing 8.1% of Valneva’s share capital at a price of €9.49 per share – see press release.

Sanyou Biopharmaceuticals, focused on R&D and services of innovative antibody drugs, and Dragon Sail Pharmaceutical, a CDMO and CMO enterprise providing high-end biological drug manufacture services, announced a long-term strategic partnershipsee full article.

Biogen and Happify Health announced a collaboration to provide a digital solution for patient education and engagement, powered by artificial intelligence (AI), to support people living with multiple sclerosis (MS) – see press release.

Inozyme Pharma, Inc., a clinical-stage rare disease company developing novel therapeutics for the treatment of abnormal mineralization, announced a partnership with Rady Children’s Institute for Genomic Medicine to advance and evaluate a novel newborn screening technology to facilitate diagnosis of genetic diseasessee full article.